(NASDAQ: AMAG) announced today that Vyleesi (bremelanotide injection), a melanocortin
receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus.
AMAG Pharmaceuticals announced that Vyleesi, a melanocortin
receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus.
Vyleesi works by activating melanocortin
receptors but the exact mechanism for improving sexual desire is unknown.
The extension locus encodes the melanocortin
1 receptor (MC1R) gene that has a seven transmembrane domains protein belonging to the G protein coupled receptors .
To create a Viagra like effect in women, Vyleesi activates melanocortin
receptors in the brain, which helps to increase sexual desire and distress.
Vyleesi is believed to bind to melanocortin
receptors in the central nervous system that are thought to be associated with sexual function.
The exact way in which Vyleesi helps stimulate sexual desire remains unclear, but it works on melanocortin
receptors on cells, the FDA said.
She said: "MC1R's task is making a protein called melanocortin
Currently, 1 emerging melanocortin
agonist has undergone phase 3 trials in the United States, and 2 testosterone-based oral agents are under investigation.
(20) MC4R is a component of the leptin system, which is expressed in the brain and is part of the melanocortin
signaling pathway and is known to play an important role in control of food intake and metabolic rate.
For the study, published in the journal Molecular Metabolism, the team measured the effects of short- and long-term exercise on two types of neurons that comprise the melanocortin